News - Biotie Therapies


Current filters:

Biotie Therapies

Popular Filters

Biotie invests in Alzheimer’s drug SYN120 as it drops epilepsy pathway

Biotie invests in Alzheimer’s drug SYN120 as it drops epilepsy pathway


Finland-based Biotie Therapies (Nasdaq OMX: BTH1V), which is focused on neurodegenerative and psychiatric…

BiotechnologyBiotie TherapiesFinancialFinlandHealthcareNeurologicalNRL-1SYN120

Lundbeck and Otsuka partner on Biotie’s nalmefene in Japan

Lundbeck and Otsuka partner on Biotie’s nalmefene in Japan


Biotie Therapies says that its partner, Lundbeck has expanded its existing alliance with Otsuka Pharmaceutical…

Asia-PacificBiotechnologyBiotie TherapiesLicensingLundbeckMarkets & MarketingnalmefeneNeurologicalSelincro

Lundbeck launches Selincro in Italy

Lundbeck launches Selincro in Italy


Danish CNS drug specialist Lundbeck has brought Selincro on the market in Italy.

Biotie TherapiesItalyLundbeckMarkets & MarketingNeurologicalPharmaceuticalSelincro

Biotie completes planned portfolio review

Biotie completes planned portfolio review


Biotie Therapies has revealed the outcome of its planned portfolio review, following its success earlier…

Biotie TherapiesLicensingLundbeckNeurelisNeurologicalNRL-1PharmaceuticalResearchSelincrotozadenantUCB

Biotie buys option to acquire Neurelis, and opportunity for epilepsy candidate


Finland-based biotech firm Biotie Therapies (Nasdaq-OMX; BTH1V) says that it has obtained an exclusive…

BiotechnologyBiotie TherapiesMergers & AcquisitionsNeurelisNeurologicalNRL-1Pharmaceutical

Launch of Biotie/Lundbeck's Selincro will see a paradigm shift in alcohol addiction market


US and European psychiatrists and US managed care organization (MCO) pharmacy directors surveyed by advisory…

Biotie TherapiesEuropeLundbeckMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalSelincro

UCB licenses global rights to tozadenant in Parkinson's disease from Biotie


Finland-based Biotie Therapies (Nasdaq-OMX: BTH1V) says that UCB (Euronext Brussels; UCB), Belgium's…

Biotie TherapiesLicensingNeurologicalPharmaceuticaltozadenantUCB

Lundbeck takes 5% stake in Biotie; amends Selincro licensing deal


Danish CNS drug specialist Lundbeck A/S (LUND: DC) said this morning that it has made an investment of…

BiotechnologyBiotie TherapiesFinancialLicensingLundbeckMergers & AcquisitionsNeurologicalPharmaceuticalSelincro

Biotie assets available for partnering; update on tozadenant


Finland-based biotech firm Biotie Therapies' (OMX: BTH1V) retention of SYN120 rights after Roche decided…

BiotechnologyBiotie TherapiesFinancialLicensingLundbeckNeurologicalResearchSelincroSYN120tozadenantUCB

Roche returns rights to Biotie Therapies SYN120


Finland-based Biotie Therapies (OMX: BTH1V) said yesterday that it is retaining global development and…

Biotie TherapiesLicensingNeurologicalPharmaceuticalRocheSYN120

Lundbeck submits Selincro in EU; Novo Nordisk files Degludec in Japan


Danish CNS drug specialist Lundbeck (LUND: DC) revealed yesterday that it has submitted a marketing authorization…

Asia-PacificBiotie TherapiesDegludecDiabetesEuropeLundbeckNeurologicalNovo NordiskPharmaceuticalRegulationSelincro

UCB pulls out of Biotie partnership on SYN118


Finland-based Biotie Therapies (Nasdaq-OMX: BTH1V) says that, as it had already expected following disappointing…

Biotie TherapiesLicensingNeurologicalPharmaceuticalUCB

Repligen to buy Novozymes Biopharma Sweden business for $23 upfront; Biotie pulls out of Newron acquisition


USA-based Repligen (Nasdaq: RGEN) says it has signed a definitive agreement to acquire the business of…

Biotie TherapiesMergers & AcquisitionsNewron PharmaNovozymesPharmaceuticalRepligensafinamide

Benefits of Biotie’s 45 million-euro buy of Newron assessed by Edison Research


Finland-based Biotie Therapies’ (OMX: BTH1V) proposed c 45 million-euro all-stock merger with Italian…

BiotechnologyBiotie TherapiesMergers & AcquisitionsNeurologicalNewron PharmaPharmaceuticalResearch

Biotie to buy Newron for 45 million euros, creating a European leader in CNS drug development


In a second acquisition this year, Finland-based biotech company Biotie Therapies (OMX: BTH1V) has entered…

BiotechnologyBiotie TherapiesMergers & AcquisitionsNeurologicalNewron PharmaPharmaceutical

Back to top